A Single Centre, Randomised, Double-blind, 2-Way Crossover Trial to Assess the Effect of Fluconazole, a CYP2C9/2C19 Inhibitor, on the Pharmacokinetics of a Single Dose of ZD4522 80 mg in Healthy Male Volunteers

Study identifier:4522IL/0048

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Single Centre, Randomised, Double-blind, 2-Way Crossover Trial to Assess the Effect of Fluconazole, a CYP2C9/2C19 Inhibitor, on the Pharmacokinetics of a Single Dose of ZD4522 80 mg in Healthy Male Volunteers

Medical condition

hypercholesterolaemia

Phase

N/A

Healthy volunteers

-

Study drug

-

Sex

-

Actual enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria